Impact of some oral hypoglycemic agents on type 2 diabetes-associated depression and reserpine-induced depression in rats: the role of brain oxidative stress and inflammation

Soliman, Eman; Essmat, Nariman; Mahmoud, Mona F.; Mahmoud, A. A.

doi:10.1007/s00210-020-01838-w

Cited by 26 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this property of the 5-HT system is not restricted to metformin, such that antidepressant-like effects accompanied by an enhancement of the serotonergic system in the cortex and the hippocampus were reported with vildagliptin, pioglitazone and glyburide in animal models of T2D. 130 Moreover, antidepressant-like activity of antidiabetic drugs has also been described in animal models of depression without metabolic impairments. For example, the PPAR-γ agonist pioglitazone prevents anhedonia and despair-like behaviours induced by the i.c.v.…”

Section: Antidepre Ssant Effec Ts Of Antid Iab E Tic Drug S In Rel Ati On With the Ac Tivati On Of The S Erotonerg I C S Ys Temmentioning

confidence: 99%

“…injection of LPS 131 and reverses such phenotype in a mouse model of reserpine-induced depressive symptoms. 130 In both studies, the antidiabetic drug used prevents or reverses the decrease in cortical and hippocampal 5-HT levels. Taken together, these results show that antidiabetic drugs display antidepressant-like properties both in clinical and preclinical studies and that such properties are mediated, in part, through the enhancement of serotonergic neurotransmission.…”

Section: Antidepre Ssant Effec Ts Of Antid Iab E Tic Drug S In Rel Ati On With the Ac Tivati On Of The S Erotonerg I C S Ys Temmentioning

confidence: 99%

See 1 more Smart Citation

The impact of insulin on the serotonergic system and consequences on diabetes‐associated mood disorders

Martin

Bullich

Guiard

et al. 2021

J Neuroendocrinology

View full text Add to dashboard Cite

The idea that insulin could influence emotional behaviours has long been suggested.However, the underlying mechanisms have yet to be solved and there is no direct and clear-cut evidence demonstrating that such action involves brain serotonergic neurones. Indeed, initial arguments in favour of the association between insulin, serotonin and mood arise from clinical or animal studies showing that impaired insulin action in type 1 or type 2 diabetes causes anxiety-and depressive symptoms along with blunted plasma and brain serotonin levels. The present review synthesises the main mechanistic hypotheses that might explain the comorbidity between diabetes and depression. It also provides a state of knowledge of the direct and indirect experimental evidence that insulin modulates brain serotonergic neurones. Finally, it highlights the literature suggesting that antidiabetic drugs present antidepressantlike effects and, conversely, that serotonergic antidepressants impact glucose homeostasis. Overall, this review provides mechanistic insights into how insulin signalling alters serotonergic neurotransmission and related behaviours bringing new targets for therapeutic options.

show abstract

Section: Antidepre Ssant Effec Ts Of Antid Iab E Tic Drug S In Rel Ati On With the Ac Tivati On Of The S Erotonerg I C S Ys Temmentioning

confidence: 99%

Section: Antidepre Ssant Effec Ts Of Antid Iab E Tic Drug S In Rel Ati On With the Ac Tivati On Of The S Erotonerg I C S Ys Temmentioning

confidence: 99%

The impact of insulin on the serotonergic system and consequences on diabetes‐associated mood disorders

Martin

Bullich

Guiard

et al. 2021

J Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…Finally, peripheral insulin resistance has been associated with anxiogenic-like responses [13]. The latter are associated with increased branched-chain amino acid plasma levels, which in turn reduce tryptophan availability in serotonin receptors [13,14]. In this context, it is of immense interest that hippocampal serotonin re-uptake was reduced among metformintreated insulin-resistant mice [14].…”

Section: Digital Featuresmentioning

confidence: 99%

“…Protection against methamphetamine-induced behavioural changes through improved neurotransmission as well as through anti-inflammatory and anti-oxidative actions [11,12] 5. Increase of branched chain amino acid levels in plasma to reduce tryptophan availability in serotonin receptors, which in turn reduce hippocampal serotonin re-uptake [13,14] reduced psychiatric hospitalisation and selfharm in subjects with serious mental illness [15]. Accordingly, we are eagerly anticipating what the future has in store for metformin in ameliorating depression among subjects with impaired glucose metabolism.…”

Section: Digital Featuresmentioning

confidence: 99%

Reduction of Depression in Diabetes: A New Pleiotropic Action of Metformin?

Papachristou

Παπάνας

2021

Diabetes Ther

View full text Add to dashboard Cite

Metformin remains the cornerstone of management for type 2 diabetes mellitus (T2DM). It is also known that it has beneficial pleiotropic actions. In addition, there is emerging evidence that this agent may prove beneficial in ameliorating depression in T2DM. The underlying mechanisms of this new action remain elusive, but experimental studies point to improved synaptic function and increased serotonin activity, along with the known inflammatory and antioxidant properties of metformin. Obviously, we need to further explore the potential utility of such antidepressant effects among T2DM subjects in everyday reality.

show abstract

“…Experimental studies revealed an association between depressive like behaviors and T2DM (Ye et al, 2017;Soliman et al, 2020). Clinically, depression has been found to negatively impact glycemic control and to increase the diabetic complications including cardiovascular diseases (Lin et al, 2010;Oladeji and Gureje, 2013).…”

Section: Introductionmentioning

confidence: 99%

Escitalopram Ameliorates Cardiomyopathy in Type 2 Diabetic Rats via Modulation of Receptor for Advanced Glycation End Products and Its Downstream Signaling Cascades

2020

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) has been recognized as a known risk factor for cardiovascular diseases. Additionally, studies have shown the prevalence of depression among people with diabetes. Thus, the current study aimed to investigate the possible beneficial effects of escitalopram, a selective serotonin reuptake inhibitor, on metabolic changes and cardiac complications in type 2 diabetic rats. Diabetes was induced by feeding the rats high fat-high fructose diet (HFFD) for 8 weeks followed by a subdiabetogenic dose of streptozotocin (STZ) (35 mg/kg, i. p.). Treatment with escitalopram (10 mg/kg/day; p. o.) was then initiated for 4 weeks. At the end of the experiment, electrocardiography was performed and blood samples were collected for determination of glycemic and lipid profiles. Animals were then euthanized and heart samples were collected for biochemical and histopathological examinations. Escitalopram alleviated the HFFD/STZ-induced metabolic and cardiac derangements as evident by improvement of oxidative stress, inflammatory, fibrogenic and apoptotic markers in addition to hypertrophy and impaired conduction. These results could be secondary to its beneficial effects on the glycemic control and hence the reduction of receptor for advanced glycation end products content as revealed in the present study. In conclusion, escitalopram could be considered a favorable antidepressant medication in diabetic patients as it seems to positively impact the glycemic control in diabetes in addition to prevention of its associated cardiovascular complications.

show abstract

Impact of some oral hypoglycemic agents on type 2 diabetes-associated depression and reserpine-induced depression in rats: the role of brain oxidative stress and inflammation

Cited by 26 publications

References 48 publications

The impact of insulin on the serotonergic system and consequences on diabetes‐associated mood disorders

The impact of insulin on the serotonergic system and consequences on diabetes‐associated mood disorders

Reduction of Depression in Diabetes: A New Pleiotropic Action of Metformin?

Escitalopram Ameliorates Cardiomyopathy in Type 2 Diabetic Rats via Modulation of Receptor for Advanced Glycation End Products and Its Downstream Signaling Cascades

Contact Info

Product

Resources

About